clinical trial · NCT06150781
Aimovig Pregnancy Exposure Registry
Amgen·—·recruiting·n = 2,842
Migraineerenumab-aooe
brief summary
The primary objective of this study is to estimate the proportion of major congenital malformations in infants of women with migraine exposed to erenumab-aooe during pregnancy compared to infants of women with migraine unexposed to erenumeb-aooe.
started
Jan 27, 2021
primary completion
Oct 28, 2027
completion
Oct 28, 2027
last updated
Nov 4, 2025
official title
GENESIS: AIMOVIG® Pregnancy Exposure Registry
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol